Clinical trials in Sofia – page 11

772 clinical trials in Sofia, Bulgaria across 17 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Sofia at a glance

772

clinical trials

Research sites17

Quick filters

772 trials in Sofia

Open in trial search

Non-small cell lung cancer

Recruiting

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo

Bulgaria

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Amgen Inc.

Contact Research Centre

Chronic spontaneous urticaria

Recruiting

A study to evaluate the efficacy and safety of lesigercept in adults with chronic spontaneous urticaria who do not have enough relief from antihistamines

Investigational

A study to evaluate the efficacy and safety of lesigercept in adults with chronic spontaneous urticaria who do not have enough relief from antihistamines

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Sponsor:Yuhan Corp.

Contact Research Centre

Dermatitis+2

Recruiting

A study to evaluate the effectiveness of NAV-240 in adults with moderate-to-severe hidradenitis suppurativa

Registered drug

A study to evaluate the effectiveness of NAV-240 in adults with moderate-to-severe hidradenitis suppurativa

Registered drug

Bulgaria

Participants:18–64 years · 65+ years
Substances:IMB 101
Sponsor:Navigator Medicines Inc.

Contact Research Centre

Acquired C1 inhibitor deficiency

Recruiting

Study to evaluate the efficacy and safety of deucrictibant for the prevention and treatment of angioedema attacks in adults with acquired angioedema

Investigational

Study to evaluate the efficacy and safety of deucrictibant for the prevention and treatment of angioedema attacks in adults with acquired angioedema

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Substances:Deucrictibant
Sponsor:Pharvaris Netherlands B.V.

Contact Research Centre

Ischaemic stroke

Recruiting

A study to evaluate the effectiveness of tenecteplase in patients with acute ischemic stroke who are more than 4.5 hours after their last known well time.

Registered drugNo placebo

A study to evaluate the effectiveness of tenecteplase in patients with acute ischemic stroke who are more than 4.5 hours after their last known well time.

Registered drugNo placebo

Bulgaria

Participants:18–64 years · 65+ years
Substances:Tenecteplase
Sponsor:Boehringer Ingelheim International GmbH

Contact Research Centre

Idiopathic pulmonary fibrosis

Recruiting

A study of the humanised IgG1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1 to treat adults with idiopathic pulmonary fibrosis

Investigational

A study of the humanised IgG1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1 to treat adults with idiopathic pulmonary fibrosis

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Substances:HUMANISED IGG1 LALAPS-YTE MONOCLONAL ANTIBODY AGAINST LYSOPHOSPHATIDIC ACID RECEPTOR 1
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Diabetic retinal oedema

Recruiting

A study to compare the efficacy and safety of AVT29 and aflibercept in patients with diabetic macular edema

Registered drugNo placebo

A study to compare the efficacy and safety of AVT29 and aflibercept in patients with diabetic macular edema

Registered drugNo placebo

Bulgaria

Participants:18–64 years · 65+ years
Substances:Aflibercept
Sponsor:Alvotech Swiss AG

Contact Research Centre

Secondary progressive multiple sclerosis

Recruiting

A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

Investigational

A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Substances:Remibrutinib
Sponsor:Novartis Pharma AG

Contact Research Centre

Chronic kidney disease+1

Recruiting

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Sponsor:Eli Lilly & Co.

Contact Research Centre

Major depression

Recruiting

A study to evaluate the effectiveness and safety of DT-101 in adults with major depressive disorder

Investigational

A study to evaluate the effectiveness and safety of DT-101 in adults with major depressive disorder

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Sponsor:Draig Therapeutics Limited

Contact Research Centre

Myasthenia gravis

Recruiting

A study of IM-101 in adults with generalized myasthenia gravis or ocular myasthenia gravis

Registered drug

A study of IM-101 in adults with generalized myasthenia gravis or ocular myasthenia gravis

Registered drug

Bulgaria

Participants:18–64 years · 65+ years
Substances:IM-101
Sponsor:Immunabs Inc.

Contact Research Centre

Metabolic dysfunction-associated liver disease

Recruiting

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Substances:LY3437943 sodium
Sponsor:Eli Lilly & Co.

Contact Research Centre

Other cities in Bulgaria

The busiest research cities in the country

All 53 cities in Bulgaria

Clinical research in Sofia

What the registry says about research in the country

01 Respiratory Research

Clinical studies focusing on respiratory infections and conditions, including trials for RSV, human metapneumovirus, and influenza vaccines in older adults. Research also includes investigations into asthma treatments and chronic rhinosinusitis management.

Respiratory Syncytial Virus (RSV)
Influenza Prevention
Chronic Rhinosinusitis
Asthma Management

02 Dermatological Studies

Comprehensive research into various skin conditions, evaluating new treatments for chronic urticaria, hidradenitis suppurativa, and different forms of psoriasis. These trials aim to improve patient outcomes through innovative therapeutic approaches.

Chronic Spontaneous Urticaria
Hidradenitis Suppurativa
Genital Psoriasis
Plaque Psoriasis

03 Autoimmune Disorders

Groundbreaking studies examining treatments for various autoimmune conditions, including multiple sclerosis, Sjögren's disease, and systemic sclerosis. Research focuses on developing targeted therapies to manage these chronic conditions.

Multiple Sclerosis
Sjögren's Disease
Systemic Sclerosis
Psoriatic Arthritis

04 Metabolic and Cardiovascular Research

Studies investigating treatments for metabolic disorders and heart conditions, including research on hypertriglyceridemia, obesity management, and heart failure prevention. Focus on both therapeutic interventions and preventive measures.

Hypertriglyceridemia
Obesity Management
Heart Failure Prevention
Cardiovascular Health

05 Oncology Research

Advanced clinical trials focusing on breast cancer treatments and blood disorders, particularly investigating new therapeutic approaches for advanced/metastatic breast cancer and myelodysplastic syndrome.

Advanced Breast Cancer
Myelodysplastic Syndrome
Targeted Therapies

Back to Bulgaria All countries